

IN THE CLAIMS:

The following is a complete listing of claims in this application.

Claims 1-78 (canceled).

79. (previously presented) A method of enhancing the biological activity of a LH-RH peptide analogue which comprises orally administering to a patient in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a peptide analogue in combination with an α -cyclodextrin derivative and excipients suitable for the gastrointestinal delivery of the peptide analogue, wherein the α -cyclodextrin derivative enhances the biological activity of the LH-RH peptide analogue when orally administered, wherein said peptide analogue has the formula (SEQ ID NO 2):

pGlu-His-Trp-Ser-Tyr-A6-A7-Arg-Pro-Z (I)

in which :

A6 is Gly, (S)-spirolactam-Pro, DAla, DLeu, DPhe, DTrp, or DSer(OBu^t);

A7 is Leu or Npg;

Z is GlyNH₂, azaGlyNH₂ or a group -NHR₂ where R₂ is ethyl; and wherein the α -cyclodextrin derivative is selected from the group consisting of methylated α -cyclodextrin, hexakis(2, 3, 6-tri-O-methyl)- α -cyclodextrin, carboxymethylated- α -cyclodextrin and phosphated α -cyclodextrin.

Claims 80-81 (canceled).

82. (previously presented) The method according to claim 79 wherein the peptide analogue is selected from the group consisting of leuprorelin, [Npg⁷]-leuprorelin, triptorelin, [Npg⁷]-triptorelin, goserelin, [Npg⁷]-goserelin, buserelin and

[Npg⁷]-buserelin.

83. (canceled).

84. (previously presented) The method according to claim 79 wherein the α -cyclodextrin derivative is hexakis(2, 3, 6-tri-O-methyl)- α -cyclodextrin.

85. (withdrawn) The method according to claim 79 wherein the pharmaceutical composition is intended for the treatment of infertility, hypogonadic or hypergonadic states.

86. (withdrawn) The method according to claim 79 wherein the pharmaceutical composition is a contraceptive agent.

87. (previously presented) The method according to claim 79 wherein the pharmaceutical composition is intended for the treatment of prostate cancer or benign prostatic hypertrophy.

88. (withdrawn and previously presented) The method according to claim 79 wherein the pharmaceutical composition is intended for the treatment of breast cancer.

89. (withdrawn and previously presented) The method according to claim 79 wherein the pharmaceutical composition is intended for the treatment of sex hormone-related benign or malignant tumors.

90. (withdrawn and previously presented) The method according to claim 79 wherein the pharmaceutical composition is intended for the treatment of sex hormone-independent but LH-RH sensitive benign or malignant tumors.

91. (withdrawn and previously presented) The method according to claim 79 wherein the pharmaceutical composition is intended for the treatment of benign or malignant

lymphoproliferative disorders.

92. (previously presented) A pharmaceutical composition for the gastrointestinal delivery by oral administration of an LH-RH peptide analogue, said composition comprising a therapeutically effective amount of a peptide analogue in combination with an α -cyclodextrin derivative and excipients suitable for the gastrointestinal delivery of the peptide analogue, wherein the α -cyclodextrin derivative enhances the biological activity of the LH-RH peptide analogue when orally administered, said LH-RH peptide analogue having the formula (SEQ ID NO 2):

pGlu-His-Trp-Ser-Tyr-A6-A7-Arg-Pro-Z . . . (I)

in which:

A6 is Gly, (S)-spirolactam-Pro, DAla, DLeu, DPhe, DTrp, or DSer(OBu^t);

A7 is Leu or Npg;

Z is GlyNH₂, D-AlaNH₂, or a group -NHR₂ where R₂ is ethyl; and wherein the α -cyclodextrin derivative is selected from the group consisting of methylated α -cyclodextrin, hexakis(2, 3, 6-tri-O-methyl)- α -cyclodextrin, carboxymethylated α -cyclodextrin and phosphated α -cyclodextrin.

Claims 93-94 (canceled).

95. (previously presented) The pharmaceutical composition according to claim 92 wherein the peptide analogue is selected from the group consisting of leuprorelin, [Npg⁷]-leuprorelin, triptorelin, [Npg⁷]-triptorelin, goserelin, [Npg⁷]-goserelin, buserelin and [Npg⁷]-buserelin.

96. (canceled).

97. (previously presented) The pharmaceutical composition according to claim 92 wherein the α -cyclodextrin derivative is hexakis(2, 3, 6-tri-O-methyl)- α -cyclodextrin.

98. (previously presented) The pharmaceutical composition according to claim 92 which further consists of a protease inhibitor and/or an absorption enhancer.

99. (previously presented) The method according to claim 79 wherein the α -cyclodextrin derivative is hexakis(2, 3, 6-tri-O-methyl)- α -cyclodextrin.